Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and ...
(WorldNews China)

― Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (“NET”) ― ― SANET-p results complement previously presented positive Phase III SANET-ep results in patients with non-pancreatic NET, including across multiple subgroups ― ― Results of both SANET-p and SANET-ep studies published in The Lancet Oncology – HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 20, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that positive results of the Phase III study of surufatinib in advanced neuroendocrine tumors – pancreatic (“SANET-p”) were...